More than one-quarter of patients with AML have an internal tandem repeat mutation in the juxtamembrane domain of the FLT3 receptor (i.e., FLT3-ITD mutation), which promotes AML progression [5,6]. Here, FLT3 is linked to acute myeloid leukemia.